Identification and management of invasive mycoses in internal medicine: A road-map for physicians

Internal and Emergency Medicine

Volumn 9, Issue 5, 2014, Pages 501-511

  Falcone, Marco ^a   Concia, Ercole ^b   Iori, Ido ^c   Lo Cascio, Giuliana ^b   Mazzone, Antonino ^d   Pea, Federico ^e   Violi, Francesco ^f   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d Hospital of Legnano   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antifungal therapy; Aspergillosis; Candidemia; Echinocandins; Internal medicine; Invasive mycoses

Indexed keywords

CANDIDIASIS, INVASIVE; DECISION TREE; HUMAN; INTERNAL MEDICINE; INVASIVE PULMONARY ASPERGILLOSIS; PATIENT CARE PLANNING;

CANDIDIASIS, INVASIVE; DECISION TREES; HUMANS; INTERNAL MEDICINE; INVASIVE PULMONARY ASPERGILLOSIS; PATIENT CARE PLANNING;

EID: 84904751606     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-014-1077-4     Document Type: Review

References (71)

1. Becksague CM, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal-infections in the United States, 1980-1990. J Infect Dis 167: 1247-1251.
2. Edmond MB, Wallace SE, McClish DK et al (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29: 239-244.
3. Andes DR, Safdar N, Baddley JW et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54: 1110-1122.
4. Mazzone A, Concia E, Falcone M, Pea F, Rossolini G (2012) Invasive fungal infections in the setting of internal medicine: an emergent challenge. Ital J Med 6(2 Suppl): 19-35.
5. Rockwood K, Hogan DB, MacKnight C (2000) Conceptualisation and measurement of frailty in elderly people. Drugs Aging 17: 295-302.
6. Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM (2010) Towards an integral conceptual model of frailty. J Nutr Health Aging 14: 175-181.
7. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59: 255-263.
8. Falcone M, Blasi F, Menichetti F, Pea F, Violi F (2012) Pneumonia in older frail patients: an up to date. Intern Emerg Med 7: 415-424.
9. Gavazzi G, Krause KH (2002) Ageing and infection. Lancet Infect Dis 2: 659-666.
10. Rajagopalan S (2005) Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 40: 990-996.
11. Luzzati R, Cavinato S, Giangreco M et al (2013) Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial Candidemia in elderly patients: a matched case-control study. Mycoses 56: 664-671.
12. Caccese R, Carfagna P, Pistilli N et al (2012) Candida thrombophlebitis of central veins: case report and review. Med Mycol 50: 299-304.
13. Falcone M, Accarpio F, Venditti M et al (2010) Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J Antimicrob Chemother 65: 2266-2267.
14. Falcone M, Russo A, De Rosa FG et al (2010) Clinical experience of anidulafungin for the treatment of patients with documented candidemia. J Chemother 22: 397-401.
15. Raad I, Hanna H, Boktour M et al (2004) Management of central venous catheters in patients with cancer and candidemia with cancer and candidemia. Clin Infect Dis 38: 1119-1127.
16. Alarcón GS (2006) Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 20: 849-875.
17. Rychly DJ, Di Piro JT (2005) Infections associated with tumor necrosis factor-a antagonists. Pharmacotherapy 25: 1181-1192.
18. Cei M, Pardelli R, Sani S, Mumoli N (2014) Local resistance patterns to antimicrobials in internal medicine: a focused report from the REGIMEN (REGistro Infezioni in MEdicina INterna) study. Clin Exp Med 14: 77-82.
19. Bassetti M, Taramasso L, Nicco E et al (2011) Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6: e24198.
20. Guastalegname M, Russo A, Falcone M, Giuliano S, Venditti M (2013) Candidemia subsequent to severe infection due to Clostridium difficile: is there a link? Clin Infect Dis 57: 772-774.
21. Donahue SP, Greven CM et al (1994) Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 101: 1302-1309.
22. Cuenca-Estrella M, Verweij PE et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18(Suppl. 7): 9-18.
23. Horvath LL, Hospenthal DR, Murray CK, Dooley DP (2003) Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J Clin Microbiol 41: 4714-4717.
24. Lai CC, Wang CY, Liu WL, Huang YT, Hsueh PR (2012) Time to blood culture positivity of different Candida species causing fungemia. J Med Microbiol 61: 701-704.
25. Posteraro B, De Pascale M, Tumbarello M et al (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1®3)-b-d-glucan assay, Candida score, and colonization index. Crit Care 15: R249.
26. Odabasi Z, Mattiuzzi G, Estey E et al (2004) β-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199-205.
27. Onishi A, Sugiyama D, Kogata Y, Saegusa J et al (2012) Diagnostic accuracy of serum 1, 3-β-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 50: 7-15.
28. Ostrosky-Zeichner L (2012) Invasive mycoses: diagnostic challenges. Am J Med 125(1A): S14-S24.
29. Hsu JL, Ruoss SJ, Bower ND et al (2011) Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol 37: 277-312.
30. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C (2010) The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 14: R222.
31. Arendrup MC, Bergmann OJ, Larsson L et al (2010) Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect 16: 855-862.
32. Sendid B, Poirot JL, Tabouret M et al (2002) Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51: 433-442.
33. Aittakorpi A, Kuusela P, Koukila-Kähkölä P et al (2012) Accurate and rapid identification of Candida spp. frequently associated with fungemia by using PCR and the microarray-based prove-it sepsis assay. J Clin Microbiol 50: 3635-3640.
34. Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl. 7): 19-37.
35. Kett DH, Shorr AF, Reboli AC et al (2011) Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 15: R253.
36. Reboli AC, Shorr AF, Rotstein C et al (2011) Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 11: 261.
37. Vazquez JA, Sobel JD (2006) Anidulafungin: a novel echinocandin. Clin Infect Dis 43: 215-222.
38. Chandrasekar PH, Sobel JD (2006) Micafungin: a new echinocandin. Clin Infect Dis 42: 1171-1178.
39. Deresinski SC, Stevens DA (2003) Caspofungin. Clin Infect Dis 36: 1445-1457.
40. Hall RG, Swancutt MA, Meek C, Leff R, Gumbo T (2013) Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother 57: 2259-2264.
41. Hall RG, Swancutt MA, Gumbo T (2011) Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 55: 5107-5112.
42. Bennett JE (2006) Echinocandins for candidemia in adults without neutropenia. N Engl J Med 355: 1154-1159.
43. Wiederhold NP, Lewis RE (2003) The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 12: 1313-1333.
44. Falcone M, Barzaghi N, Carosi G et al (2009) Italian study on endocarditis. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 88: 160-168.
45. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M (2013) Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51: 2571-2581.
46. Segal BH, Walsh TJ (2006) Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 173: 707-717.
47. Vandecasteele SJ, Meersseman W, Wilmer A et al (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170: 621-625.
48. Ader F, Nseir S, Le Berre R et al (2005) Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 11: 427-429.
49. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M (2011) Invasive aspergillosis in patients with liver disease. Med Mycol 49: 406-413.
50. Falcone M, Shindo Y, Venditti M, Kollef MH (2011) Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis 15: e545-e550.
51. Bulpa P, Dive A, Sibille Y (2007) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30: 782-800.
52. De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821.
53. Cornet M, Mallat H, Somme D et al (2003) Fulminant invasive pulmonary aspergillosis in immunocompetent patients-a two-case report. Clin Microbiol Infect 9: 1224-1227.
54. Denning DW (2004) Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 170: 580-581.
55. Petri MG, Konig J, Moecke HP et al (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intens Care Med 23: 317-325.
56. Peter E, Bakri F, Ball DM, Cheney RT, Segal BH (2002) Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis 35: e54-e56.
57. Balloy V, Huerre M, Latge JP, Chignard M (2005) Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 73: 494-503.
58. Rello J, Esandi ME, Mariscal D et al (1998) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 26: 1473-1475.
59. Carfagna P, Brandimarte F, Caccese R et al (2011) Fatal invasive pulmonary aspergillosis complicating influenza A (H1N1)v infection. Mycoses 54: 549-551.
60. Meersseman W, Lagrou K, Maertens J et al (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177: 27-34.
61. Maris C, Martin B, Creteur J et al (2007) Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Arch 450: 329-333.
62. Russo A, Falcone M, Vena A et al (2011) Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. J Chemother 23: 290-294.
63. Cornillet A, Camus C, Nimubona S et al (2006) Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey. Clin Infect Dis 43: 577-584.
64. Nucci M, Nouér SA, Grazziutti M et al (2010) Probable invasive probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 51: 1273-1280.
65. Guinea J, Torres-Narbona M, Gijòn P et al (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16: 870-877.
66. Meersseman W, Lagrou K, Maertens J, van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45: 205-216.
67. Kwak EJ, Husain S, Obman A et al (2004) Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 42: 435-438.
68. Kimura SI, Odawara J, Aoki T et al (2009) Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. Int J Hematol 90: 463-470.
69. Acosta J, Catalan M, del Palacio-Peréz-Medel A et al (2011) A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1 → 3)-β-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 17: 1053-1060.
70. Walsh TJ, Anaissie EJ, Denning DW et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
71. Crandon JL, Banevicius MA, Fang AF et al (2009) Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 53: 5102-5107.